ES2136065T3 - Regulacion de la produccion de inmunoglobulinas por la interleucina-9. - Google Patents

Regulacion de la produccion de inmunoglobulinas por la interleucina-9.

Info

Publication number
ES2136065T3
ES2136065T3 ES91918691T ES91918691T ES2136065T3 ES 2136065 T3 ES2136065 T3 ES 2136065T3 ES 91918691 T ES91918691 T ES 91918691T ES 91918691 T ES91918691 T ES 91918691T ES 2136065 T3 ES2136065 T3 ES 2136065T3
Authority
ES
Spain
Prior art keywords
interleukin
production
regulation
immunoglobulin production
ige
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91918691T
Other languages
English (en)
Inventor
Bernard Dugas
Catherine Druez
Pierre Braquet
Jean-Michel Inst Mencia-Huerta
Catherine Uyttenhove
Jean-Christophe Av Hip Renauld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ipsen Pharma SAS
Ludwig Cancer Research
Original Assignee
Ludwig Institute for Cancer Research Ltd
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS, Ludwig Cancer Research filed Critical Ludwig Institute for Cancer Research Ltd
Application granted granted Critical
Publication of ES2136065T3 publication Critical patent/ES2136065T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2033—IL-5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Transceivers (AREA)
  • Mobile Radio Communication Systems (AREA)

Abstract

SE DESCRIBE UN METODO PARA LA PRODUCCION DE INHIBICION DE IGE Y UN METODO PARA LA PRODUCCION DE INCREMENTO DE IGG. LOS METODOS ESTAN RELACIONADOS AL PAPEL DEL INTERLEUQUIN PRODUCCION DE ANTICUERPOS. DE FORMA ESPECIFICA, LA PRODUCCION DE IGG ESTA POTENCIADA MEDIANTE LA ADMINISTRACION O A UN SUJETO O A UN CULTIVO CELULAR DE UNA COMBINACION DE INTERLEUQUIN E INTERLEUQUIN LA ADMINISTRACION DE UNA CANTIDAD DE INHIBIDOR INTERLEIQUIN 9 AL SUJETO.
ES91918691T 1990-10-05 1991-10-01 Regulacion de la produccion de inmunoglobulinas por la interleucina-9. Expired - Lifetime ES2136065T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/593,238 US5132109A (en) 1990-10-05 1990-10-05 Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof

Publications (1)

Publication Number Publication Date
ES2136065T3 true ES2136065T3 (es) 1999-11-16

Family

ID=24373963

Family Applications (2)

Application Number Title Priority Date Filing Date
ES91918691T Expired - Lifetime ES2136065T3 (es) 1990-10-05 1991-10-01 Regulacion de la produccion de inmunoglobulinas por la interleucina-9.
ES98200841T Expired - Lifetime ES2194273T3 (es) 1990-10-05 1991-10-01 Regulacion de la produccion de inmunoglobulinas por la interleucina-9.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES98200841T Expired - Lifetime ES2194273T3 (es) 1990-10-05 1991-10-01 Regulacion de la produccion de inmunoglobulinas por la interleucina-9.

Country Status (11)

Country Link
US (1) US5132109A (es)
EP (2) EP0553198B1 (es)
JP (2) JP3205754B2 (es)
AT (2) ATE182079T1 (es)
AU (2) AU646509B2 (es)
CA (1) CA2093434C (es)
DE (2) DE69133225T2 (es)
DK (2) DK0553198T3 (es)
ES (2) ES2136065T3 (es)
GR (1) GR3031518T3 (es)
WO (1) WO1992005698A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU669889B2 (en) * 1992-03-09 1996-06-27 Ludwig Institute For Cancer Research Nucleic acid sequences coding for or complementary to nucleic acid sequences coding for interleukin 9 receptor
DE4322330A1 (de) * 1992-08-31 1994-03-03 Behringwerke Ag Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
US6911887B1 (en) 1994-09-12 2005-06-28 Matsushita Electric Industrial Co., Ltd. Inductor and method for producing the same
AU2007202406B2 (en) * 1995-08-24 2010-08-12 Ligand Pharmaceuticals Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
CA2666298A1 (en) * 1995-08-24 1997-03-06 Genaera Corporation Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
ZA967182B (en) * 1995-08-24 1998-05-25 Magainin Pharma Asthma associated factors as targets for treating atopic allergies including asthma and related disorders.
US5830454A (en) * 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9
WO1998024904A2 (en) 1996-12-02 1998-06-11 Magainin Pharmaceuticals Inc. Il-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
CA2689842A1 (en) * 1996-12-02 1998-06-11 Genaera Corporation Il-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
WO2002100432A1 (en) 2001-06-08 2002-12-19 Genaera Corporation Methods for the modulation of il-13
JP4270974B2 (ja) 2003-08-04 2009-06-03 本田技研工業株式会社 車両における燃料タンクの配置構造
US20100219541A1 (en) 2007-09-28 2010-09-02 Konica Minolta Opto, Inc. Method for manufacturing optical device
EP2759395A1 (en) 2008-03-19 2014-07-30 Konica Minolta Opto, Inc. Method for producing a wafer lens
CN101970198B (zh) 2008-03-19 2013-05-29 柯尼卡美能达精密光学株式会社 晶片透镜的制造方法
WO2011136138A1 (ja) 2010-04-27 2011-11-03 コニカミノルタオプト株式会社 撮像用レンズ、ウエハレンズ、ウエハレンズ積層体、撮像用レンズの製造方法、撮像用レンズの中間物、撮像用レンズの中間物の製造方法
US9828087B2 (en) * 2016-01-27 2017-11-28 Honeywell International Inc. Systems and methods for ground effect ceiling limit display

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US511951A (en) * 1894-01-02 Chusetts
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US4946945A (en) * 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
US5208218A (en) * 1988-09-19 1993-05-04 Ludwig Institute For Cancer Research T cell growth factor glycoproteins
US5580753A (en) * 1989-05-23 1996-12-03 Ludwig Institute For Cancer Research DNA encoding the human cytokine, interleukin-9
IE910916A1 (en) * 1990-03-23 1991-09-25 Ludwig Inst For Cancer Res Gsf Method for enhanced growth and proliferation of mast cells

Also Published As

Publication number Publication date
DE69131450D1 (de) 1999-08-19
AU646509B2 (en) 1994-02-24
EP0553198A1 (en) 1993-08-04
DE69131450T2 (de) 2000-03-30
ES2194273T3 (es) 2003-11-16
AU5243493A (en) 1994-02-17
EP0553198B1 (en) 1999-07-14
GR3031518T3 (en) 2000-01-31
ATE182079T1 (de) 1999-07-15
WO1992005698A1 (en) 1992-04-16
JPH06502404A (ja) 1994-03-17
DK0903150T3 (da) 2003-07-21
EP0903150A1 (en) 1999-03-24
DE69133225D1 (de) 2003-04-24
EP0903150B1 (en) 2003-03-19
CA2093434C (en) 1999-08-10
DK0553198T3 (da) 1999-12-27
JP2001253835A (ja) 2001-09-18
AU8760791A (en) 1992-04-28
JP3205754B2 (ja) 2001-09-04
AU656493B2 (en) 1995-02-02
DE69133225T2 (de) 2004-02-19
EP0553198A4 (en) 1994-08-17
US5132109A (en) 1992-07-21
CA2093434A1 (en) 1992-04-06
ATE234632T1 (de) 2003-04-15

Similar Documents

Publication Publication Date Title
ES2136065T3 (es) Regulacion de la produccion de inmunoglobulinas por la interleucina-9.
DK0497706T3 (da) Termoformbar komposition, fremgangsmåde til fremstilling heraf samt anvendelse heraf med henblik på at opnå termoformede emner
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
EP0216454A3 (en) Method of promoting animal growth
FI903827A0 (fi) Foerfarande foer reducering av immunoglobulin e-responser.
FI870502A0 (fi) Menetelmä ristisuojaavien ihmisen monoklonaalisten vasta-aineiden valmistamiseksi ja vasta-ainetta tuottava solulinja
NO172596C (no) Apolipoprotein b-spesifikke monoklonale antistoffer produsert av to nye hybridomer, anvendelse av disse og diagnostiske systemer inneholdende disse
EP0339163A3 (en) Monoclonal antibodies specific for hiv and hybridomas for their production
FI851619A7 (fi) Menetelmä epifyyttikasviasetelmien kasvatusta ja kuljetusta varten.
NL940019I1 (nl) Remming van het infecterende karakter in vitro en het cytopatische effect van htlv-iii/lav door 2',3'-didesoxycytidine
DE59309740D1 (de) Lyopilisierte, wirkstoffhaltige emulsion
KR900012626A (ko) 하이브리드 단백질, 이의 생산방법 및 이를 함유하는 약제학적 조성물
ES2164211T3 (es) Procedimiento mejorado para la fabricacion de sal de 5-(alcoximetil)piridin-2,3-dicarboxilato.
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
ATE41927T1 (de) Phenylalkylamine - bioregulatoren.
ES536028A0 (es) Un procedimiento para producir interferon inmune humano recombinante intacto
DE69124317D1 (de) Monoklonale Antikörper gegen Leptosphaeria
GB8811342D0 (en) Expression of antibody heavy & light chain variable domains as active hetero-dimer in myeloma cells
ATE26411T1 (de) Verfahren fuer die reduzierung des so2- und/oder nox-gehaltes in rauchgas.
SU1692146A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus l. - продуцент моноклональных антител к 146 s-компоненту вируса ящура o
ATE31623T1 (de) Injizierbare zusammensetzungen von bbm-928a.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 553198

Country of ref document: ES